Understanding the Class Action Against Actinium Pharmaceuticals
Levi & Korsinsky, LLP, a prominent law firm, is notifying investors regarding a class action securities lawsuit against Actinium Pharmaceuticals, Inc. (NYSE: ATNM). This lawsuit is aimed at recovering losses for shareholders who were negatively impacted by alleged securities fraud involving the company.
What Led to the Class Action?
This class action centers around significant claims that occurred over a specific period. The lawsuit alleges that certain statements made by the company were misleading or false. This has raised serious concerns among investors regarding the authenticity of the information provided by Actinium Pharmaceuticals.
Details of the Allegations
According to the filed complaint, it is claimed that key information pertaining to the Phase 3 Sierra trial was misrepresented to investors. Specifically, the lawsuit points out that the data regarding the company's targeted radiotherapy, Iomab-B, was unlikely to meet the FDA's requirements for approval. This raises questions about the reliability of the analyses shared with the FDA, which indicated a trend towards improved overall survival.
Implications of the Lawsuit
The fallout from the alleged misstatements has resulted in considerable investor concern. Should the FDA refuse to review or approve the Iomab-B BLA, it could have a detrimental impact on the company's future and its share price. Therefore, if you were affected during the timeline of the supposed fraud, you might be entitled to participate in compensation claims.
What Should Investors Do Next?
Investors who have incurred losses during the timeframe of October 31, 2022, to August 2, 2024, are encouraged to act swiftly. The deadline to request appointment as lead plaintiff in the class action is approaching. Engaging as a lead plaintiff, however, is not a prerequisite to sharing in any potential recovery.
No Cost to Participate
One of the most compelling aspects of this lawsuit is that participants do not have to incur any upfront costs or fees to join. Actinium Pharmaceuticals investors can participate without any financial burden, making it an accessible opportunity for many.
Why Choose Levi & Korsinsky?
Levi & Korsinsky has a noteworthy track record in representing investors in complex securities litigation. With over two decades of experience, the firm has recovered substantial sums for its clients and has earned a reputation as one of the top securities litigation firms in the country. Their dedicated team, which comprises over 70 professionals, is committed to supporting clients through the legal process.
Contact Information for Interested Investors
If you're interested in learning more about the class action against Actinium Pharmaceuticals, you can reach out to Levi & Korsinsky directly. Investors may contact Joseph E. Levi, Esq. by phone at (212) 363-7500 for further assistance and information.
Frequently Asked Questions
What is the class action against Actinium Pharmaceuticals?
The class action lawsuit is aimed at recovering losses for investors affected by alleged securities fraud involving Actinium Pharmaceuticals.
What are the key allegations in the lawsuit?
The lawsuit claims that the company misrepresented critical data related to the FDA's guidelines for the approval of Iomab-B.
How can I participate in the class action?
Investors affected during the specified timeline can participate by contacting Levi & Korsinsky before the deadline.
Are there any costs associated with participating?
No, there are no costs or out-of-pocket expenses to join the class action.
Why should I choose Levi & Korsinsky?
The firm has a strong history of successful outcomes for investors and is recognized as a leader in securities litigation.
